Pharmaceutical Sector

Laurus Labs Share Price Jumps 2 Percent; KRChoksey downgrades to Accumulate Citing Lower than Expected Quarterly Performance

Keshav Mehta 28 October 2024
Laurus Labs Share Price Jumps 2 Percent; KRChoksey downgrades to Accumulate Citing Lower than Expected Quarterly Performance

KRChoksey has downgraded its stance on Laurus Labs to "ACCUMULATE" from "BUY," with a revised target price of Rs 489, implying a modest 5.4% upside from the current price of Rs 464.

Piramal Pharma Share Price Could Reach Rs 310; 21% Upside Suggested by Motilal Oswal

Umesh Desai 28 October 2024
Piramal Pharma Share Price Could Reach Rs 310; 21% Upside Suggested by Motilal Oswal

Motilal Oswal has issued a BUY call on Piramal Pharma with a revised target price of Rs 310, indicating a 21% upside from its current market price of Rs 256.

Intellia Therapeutics (NTLA) Stock Price Could Touch $85 in Long Term: Morningstar Research

Steve Allen 28 October 2024
Intellia Therapeutics (NTLA) Stock Price Could Touch $85 in Long Term: Morningstar Research

Morningstar’s recent analysis suggests a "Buy" on Intellia Therapeutics, assigning a fair value of $85 per share, while the current trading price is significantly lower at $15.85.

Sanofi SA (ADR: SNY) Stock Price Could Reach $63: Morningstar Research

Steve Allen 27 October 2024
Sanofi SA (ADR: SNY) Stock Price Could Reach $63: Morningstar Research

Morningstar has issued a BUY recommendation on Sanofi SA, with an upgraded fair value target of $63 from $61 due to consistent revenue growth and strong performance in immunology and vaccine divisi

Longboard Pharmaceuticals Stock Price Jumps as Lundbeck A/S Acquires Controlling Stake for $60 per Share

Keshav Seth 15 October 2024
Longboard Pharmaceuticals Stock Price Jumps as Lundbeck A/S Acquires Controlling Stake for $60 per Share

H. Lundbeck A/S, a prominent Danish pharmaceutical company, has announced its largest-ever acquisition, agreeing to buy U.S.-based Longboard Pharmaceuticals for $2.6 billion.

IPCA Laboratories Share Price in Focus as Motilal Oswal Suggests BUY Call with 18% Upside Potential

Akash Verma 15 October 2024
IPCA Laboratories Share Price in Focus as Motilal Oswal Suggests BUY Call with 18% Upside Potential

Motilal Oswal's research report has upgraded IPCA Laboratories to a "BUY" recommendation with a target price of Rs 1,950, an upside of 18% from its current market price of Rs 1,659.

Pages